Wall Street analyst estimates for Viking Therapeutics, Inc. (VKTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß).
Consensus price target
$82.00 (+214 % vs price $26.09)
between $34.00 and $120.00 · 5 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $7.2M | $7.2M – $7.2M | -$5.32 | 13 |
| 2027E | $7.3M | $7.3M – $7.3M | -$5.15 | 15 |
| 2028E | $217M | $208M – $227M | -$3.93 | 15 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 22 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 24 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-10 | $-1.38 | ||
| 2026-10-28 | $-1.55 | $-1.06 | -46.2% |
| 2026-07-29 | $-1.10 | $-1.23 | +10.6% |
| 2026-04-29 | $-1.37 | $-1.01 | -35.6% |
| 2026-02-11 | $-1.38 | $-0.89 | -55.1% |
| 2025-10-22 | $-0.81 | $-0.70 | -15.7% |
| 2025-07-23 | $-0.58 | $-0.44 | -31.8% |
| 2025-04-23 | $-0.41 | $-0.34 | -20.6% |
Valuation Ratios
| Price / Book | 5.23 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $260,000 | 0 | 0 | 0 | 0 | 0 | $431,000 |
| Gross Profit | 0 | 0 | 0 | -$260,000 | 0 | 0 | 0 | 0 | 0 | -$431,000 |
| Research & Development | $9.0M | $13.7M | $19.0M | $23.6M | $31.9M | $45.0M | $54.2M | $63.8M | $101.6M | $345.0M |
| Selling, General & Admin | $4.8M | $5.3M | $7.1M | $8.9M | $10.7M | $10.7M | $16.1M | $37.0M | $49.3M | $48.4M |
| Operating Expenses | $13.8M | $19.1M | $26.2M | $32.4M | $42.7M | $55.7M | $70.4M | $100.8M | $150.9M | $393.3M |
| Operating Income | -$13.8M | -$19.1M | -$26.2M | -$32.7M | -$42.7M | -$55.7M | -$70.4M | -$100.8M | -$150.9M | -$393.3M |
| EBITDA | -$10.8M | $442,882 | $4.7M | -$25.4M | -$39.1M | -$54.7M | -$68.5M | -$85.5M | -$109.5M | -$359.2M |
| Interest Expense | $2.0M | $2.0M | $562,000 | $146,000 | $106,000 | $18,000 | $59,000 | $88,000 | $94,000 | 0 |
| Pre-tax Income | -$14.7M | -$20.6M | -$22.1M | -$25.8M | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$14.7M | -$20.6M | -$22.1M | -$25.8M | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| EPS | -$0.90 | -$0.79 | -$0.38 | -$0.36 | -$0.50 | -$0.70 | -$0.88 | -$0.91 | -$1.01 | -$3.19 |
| EPS (Diluted) | -$0.90 | -$0.79 | -$0.38 | -$0.36 | -$0.50 | -$0.70 | -$0.88 | -$0.91 | -$1.01 | -$3.19 |
| Shares Outstanding (Diluted) | 16.3 M | 26.0 M | 57.6 M | 72.0 M | 72.6 M | 77.2 M | 76.8 M | 94.3 M | 109.0 M | 112.7 M |
Price
| Price | $26.09 (closing price, November 3, 2026) |
| Market Cap | $3.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: MDGL · NAMS · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of VKTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks